# Tumor-Specific T-Cells (cCTL:GL01) for Advanced Gastrointestinal Cancer

> **NCT07735065** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Gastrointestinal Cancer

## Interventions

- **DRUG:** Biological/Vaccine

## Key facts

- **NCT ID:** NCT07735065
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735065, "Tumor-Specific T-Cells (cCTL:GL01) for Advanced Gastrointestinal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*